The Vanguard Group, Inc. has recently announced that it has increased stake in Nuvation Bio Inc. (NYSE:NUVB) by 0.09%. After grabbing 12.47 million shares, the institutional investor is now in possession of 11813.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 5.74% having worth around $27.44 million. Moreover, BlackRock Fund Advisors increased its share by 40631.0 to have a control over 8.78 million shares. And SSgA Funds Management, Inc. raised its holdings to 0.12 million shares by acquiring 3.07 million shares or 1.41% of the stake.
Nuvation Bio Inc. (NUVB) concluded trading on 11/23/22 at a closing price of $1.84, with 0.48 million shares of worth about $0.89 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -47.73% during that period and on Wednesday the price saw a gain of about 1.10%. Currently the company’s common shares owned by public are about 218.30M shares, out of which, 159.62M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 7 analysts are covering the NUVB stock and their offered price forecasts bring an average price target of $4.60. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $6.00 and could fall to a lowest price of $2.50. The stock’s current price level is 60.0% above of average price target set by the analysts, while a rise to estimated low would result in gain of 26.4% for the stock. However, touching the estimated high of $6.00 would mean a gain of 69.33% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 3 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 3 selling transactions, insiders dumped 4,400,000 shares.
Fidelity Contrafund, Fidelity Growth Company Fund, and Vanguard Total Stock Market Index are the top 3 mutual funds which are holding stakes in Nuvation Bio Inc. Fidelity Contrafund is currently holding 10.45 million shares of worth totaling $22.99 million. The company recently came selling 21977.0 shares which brought its stake up to 4.81% of the company’s outstanding shares. Vanguard Total Stock Market Index, after buying 4.18 million shares, have now control over 1.92% of the stake in the company. It holds 0.0 shares of worth $9.19 million.
Nuvation Bio Inc. (NYSE: NUVB) started trading at $1.77, below -$0.05 from concluding price of the previous day. However, the stock later moved at a day high price of 1.8601, or with a gain of 1.10%. Stock saw a price change of -4.66% in past 5 days and over the past one month there was a price change of -14.42%. Year-to-date (YTD), NUVB shares are showing a performance of -78.35% which decreased to -80.11% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.77 but also hit the highest price of $10.45 during that period. The average intraday trading volume for Nuvation Bio Inc. shares is 617.31K. The stock is currently trading -9.52% below its 20-day simple moving average (SMA20), while that difference is down -14.26% for SMA50 and it goes to -49.22% lower than SMA200.
The Vanguard Group, Inc. acquired 12.47 million shares of Nuvation Bio Inc. having value of about $27.44 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 11813.0 shares in the company valued at close to $21735.92, or have control over 0.09% stake in the company. Nuvation Bio Inc. (NYSE: NUVB) currently have 218.30M outstanding shares and institutions hold larger chunk of about 65.30% of that. Holding of mutual funds in the company is about 35.38% while other institutional holders and individual stake holders have control over 43.02% and 22.44% of the stake respectively.
The stock has a current market capitalization of $417.04M. It has posted earnings per share of -$0.51 in the same period. It has Quick Ratio of 48.60 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NUVB, volatility over the week remained 5.00% while standing at 5.94% over the month.
Analysts are in expectations that Nuvation Bio Inc. (NUVB) stock would likely to be making an EPS of -$0.14 in the current quarter, while forecast for next quarter EPS is -$0.13 and it is -$0.46 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.17 which is -$0.11 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.11 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -48.60% while it is estimated to increase by 10.00% in next year.
Analysts at 7 brokerage firms have issued recommendations for the Nuvation Bio Inc. (NUVB)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 7 Wall Street analysts, 5 recommended a “Buy” rating, while 2 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Coverage by BMO Capital Markets stated Nuvation Bio Inc. (NUVB) stock as a Market perform in their note to investors on August 02, 2022, suggesting a price target of $2.50 for the stock. On May 04, 2022, H.C. Wainwright Initiated their recommendations, while on October 15, 2021, BTIG Research Resumed their ratings for the stock with a price target of $16. Stock get an Outperform rating from RBC Capital Mkts on April 06, 2021.